Get started
Author

Scott Owen

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
2026 · Patrick Y. Wen, Donald A. Berry, et al. · Journal of Clinical Oncology · 12
PDF
Abstract CT300: Taletrectinib in tyrosine kinase inhibitor (TKI)-naïve patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II
2026 · Lyudmila Bazhenova, Jorge Nieva, et al. · Cancer Research · 2
Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer
2026 · Danny Nguyen, Se-Hoon Lee, et al. · European Journal of Cancer
PP01.31: Long-Term Treatment with First-Line Amivantamab Plus Lazertinib: Impact of Treatment Discontinuation, Maintenance, and Early Adverse Event Management on Duration of Therapy
2026 · Danny Nguyen, Alexander I. Spira, et al. · Journal of Thoracic Oncology
Abstract LB474: Impact of first-line (1L) amivantamab-lazertinib vs osimertinib on second-line (2L) progression-free survival (PFS)
2026 · David R. Spigel, Danny Nguyen, et al. · Cancer Research
Works count: 5
Citation count: 13
H-index: 2
I10-index: 1
Year
Topic
Type